Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 630

1.

Patterns of practice in the radiation therapy management of rectal cancer: survey of the Interregional Group Piedmont, Valle d'Aosta and Liguria of the "Associazione Italiana di Radioterapia Oncologica (AIRO)".

Di Genesio Pagliuca M, Turri L, Munoz F, Melano A, Bacigalupo A, Franzone P, Sciacero P, Tseroni V, Vitali ML, Delmastro E, Scolaro T, Marziano C, Orsatti M, Tessa M, Rossi A, Ballare A, Moro G, Grasso R, Krengli M.

Tumori. 2013 Jan-Feb;99(1):61-7. doi: 10.1700/1248.13790.

PMID:
23549002
2.

Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial.

Arbea L, Martínez-Monge R, Díaz-González JA, Moreno M, Rodríguez J, Hernández JL, Sola JJ, Ramos LI, Subtil JC, Nuñez J, Chopitea A, Cambeiro M, Gaztañaga M, García-Foncillas J, Aristu J.

Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):587-93. doi: 10.1016/j.ijrobp.2011.06.2008. Epub 2011 Nov 11.

PMID:
22079731
3.

Radiotherapy in Italy for non-small cell lung cancer: patterns of care survey.

Ramella S, Maranzano E, Frata P, Mantovani C, Lazzari G, Menichelli C, Navarria P, Pergolizzi S, Salvi F.

Tumori. 2012 Jan-Feb;98(1):66-78. doi: 10.1700/1053.11502.

PMID:
22495704
4.

Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT₃NxM0, low rectal cancer: a phase II study.

Ofner D, Devries AF, Schaberl-Moser R, Greil R, Rabl H, Tschmelitsch J, Zitt M, Kapp KS, Fastner G, Keil F, Eisterer W, Jäger R, Offner F, Gnant M, Thaler J; TAKO 05/ABCSG R-02 Trial Investigators.

Strahlenther Onkol. 2011 Feb;187(2):100-7. doi: 10.1007/s00066-010-2182-6. Epub 2011 Jan 21.

PMID:
21267531
5.

Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.

Valentini V, Morganti AG, Gambacorta MA, Mohiuddin M, Doglietto GB, Coco C, De Paoli A, Rossi C, Di Russo A, Valvo F, Bolzicco G, Dalla Palma M; Study Group for Therapies of Rectal Malignancies (STORM).

Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1129-39. Epub 2006 Jan 18.

PMID:
16414206
6.

Pilot study of intense neoadjuvant chemoradiotherapy for locally advanced rectal cancer: retrospective review of a phase II study.

Xu BH, Chi P, Guo JH, Guan GX, Tang TL, Yang YH, Chen MQ, Song JY, Feng CY.

Tumori. 2014 Mar-Apr;100(2):149-57. doi: 10.1700/1491.16399.

7.

Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial.

Dunst J, Debus J, Rudat V, Wulf J, Budach W, Hoelscher T, Reese T, Mose S, Roedel C, Zuehlke H, Hinke A.

Strahlenther Onkol. 2008 Sep;184(9):450-6. doi: 10.1007/s00066-008-1751-4. Epub 2008 Sep 19.

PMID:
19016023
8.

Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer.

Chau I, Brown G, Cunningham D, Tait D, Wotherspoon A, Norman AR, Tebbutt N, Hill M, Ross PJ, Massey A, Oates J.

J Clin Oncol. 2006 Feb 1;24(4):668-74.

PMID:
16446339
9.

Oxaliplatin with raltitrexed and preoperative radiotherapy in T3-T4 extraperitoneal rectal cancer. A dose finding study.

Lupattelli M, Bellavita R, Natalini G, Giovenali P, Sidoni A, Castagnoli P, Corgna E, Draghini L, Trippolini R, Aristei C.

Tumori. 2006 Nov-Dec;92(6):474-80.

PMID:
17260486
10.

A phase II study of neoadjuvant chemoradiotherapy with oxaliplatin and capecitabine for rectal cancer.

Zhao L, Bai C, Shao Y, Guan M, Jia N, Xiao Y, Qiu H, Zhang F, Yang T, Zhong G, Chen S.

Cancer Lett. 2011 Nov 28;310(2):134-9. doi: 10.1016/j.canlet.2011.06.026. Epub 2011 Jul 5.

PMID:
21782322
11.

Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study.

Fernández-Martos C, Pericay C, Aparicio J, Salud A, Safont M, Massuti B, Vera R, Escudero P, Maurel J, Marcuello E, Mengual JL, Saigi E, Estevan R, Mira M, Polo S, Hernandez A, Gallen M, Arias F, Serra J, Alonso V.

J Clin Oncol. 2010 Feb 10;28(5):859-65. doi: 10.1200/JCO.2009.25.8541. Epub 2010 Jan 11.

PMID:
20065174
12.

Risk-adapted adjuvant chemotherapy after concomitant fluoropyrimidine-radiotherapy neoadjuvant treatment for patients with resectable cT3-4 or N+ rectal cancer.

Sastre J, Custodio A, Sanchez JC, Ortega L, Rodriguez L, Puente J, Corona J, Alfonso R, de las Heras M, Dıaz-Rubio E.

Anticancer Drugs. 2011 Feb;22(2):185-90.

PMID:
21218606
13.

Preoperative capecitabine and pelvic radiation in locally advanced rectal cancer--is it equivalent to 5-FU infusion plus leucovorin and radiotherapy?

Chan AK, Wong AO, Jenken DA.

Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1413-9. doi: 10.1016/j.ijrobp.2009.03.048.

PMID:
20338475
14.

Current options for the management of rectal cancer.

O'Neil BH, Tepper JE.

Curr Treat Options Oncol. 2007 Oct;8(5):331-8. doi: 10.1007/s11864-007-0048-7. Review.

PMID:
18181024
15.

Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial.

Uehara K, Hiramatsu K, Maeda A, Sakamoto E, Inoue M, Kobayashi S, Tojima Y, Yoshioka Y, Nakayama G, Yatsuya H, Ohmiya N, Goto H, Nagino M.

Jpn J Clin Oncol. 2013 Oct;43(10):964-71. doi: 10.1093/jjco/hyt115. Epub 2013 Aug 9.

PMID:
23935207
16.

Role of neoadjuvant treatment in cT3N0M0 rectal cancer.

Pasetto LM, Friso ML, Pucciarelli S, Basso U, Rugge M, Sinigaglia G, Rossi E, Compostella A, Toppan P, Agostini M, Monfardini S.

Anticancer Res. 2008 Nov-Dec;28(6B):4129-35.

17.

Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer.

Wong SJ, Winter K, Meropol NJ, Anne PR, Kachnic L, Rashid A, Watson JC, Mitchell E, Pollock J, Lee RJ, Haddock M, Erickson BA, Willett CG.

Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):1367-75. doi: 10.1016/j.ijrobp.2011.05.027. Epub 2011 Jul 19.

18.

Chemoradiotherapy followed by surgery in rectal cancer: improved local control using a moderately high pelvic radiation dose.

Lee SH, Lee KC, Choi JH, Oh JH, Baek JH, Park SH, Shin DB.

Jpn J Clin Oncol. 2008 Feb;38(2):112-21. doi: 10.1093/jjco/hym164. Epub 2008 Feb 8.

PMID:
18263881
19.

Phase I dose escalating trial of hyperfractionated pre-operative chemoradiation for locally advanced rectal cancer.

Movsas B, Hanlon AL, Lanciano R, Scher RM, Weiner LM, Sigurdson ER, Hoffman JP, Eisenberg BL, Cooper HS, Provins S, Coia LR.

Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):43-50.

PMID:
9747818
20.

A phase II trial of neoadjuvant IMRT-based chemoradiotherapy followed by one cycle of capecitabine for stage II/III rectal adenocarcinoma.

Zhu J, Gu W, Lian P, Sheng W, Cai G, Shi D, Cai S, Zhang Z.

Radiat Oncol. 2013 May 29;8:130. doi: 10.1186/1748-717X-8-130.

Supplemental Content

Support Center